Drugs / Liposome Adriamycin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05006469 | Jun 2021 → May 2023 | plasma cell myeloma | Liao Aijun | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05887726 Background | Aug 2023 → Aug 2024 | diffuse large B-cell lymphoma | Liaoning Cancer Hospital & Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposome Adriamycin | “Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po.” NCT05006469 ↗1“Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)” NCT05887726 ↗ |
| Route | Intravenous | “Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)” NCT05887726 ↗ |